Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Average Rating of “Hold” from Brokerages

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has been given a consensus rating of “Hold” by the five brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $5.00.

A number of research firms have commented on CTXR. Wall Street Zen cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Zacks Research raised Citius Pharmaceuticals to a “hold” rating in a research note on Tuesday, May 19th. HC Wainwright reiterated a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Citigroup reissued a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th.

Citius Pharmaceuticals Stock Down 0.7%

Shares of CTXR stock opened at $0.58 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.84 and a quick ratio of 0.40. Citius Pharmaceuticals has a one year low of $0.47 and a one year high of $2.19. The company’s fifty day moving average price is $0.59 and its 200-day moving average price is $0.67. The company has a market capitalization of $15.95 million, a price-to-earnings ratio of -0.35 and a beta of 1.00.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. Sell-side analysts expect that Citius Pharmaceuticals will post -2.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the second quarter worth about $32,000. NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Asset Advisory Group Inc. bought a new stake in Citius Pharmaceuticals in the 4th quarter worth approximately $46,000. BlackRock Inc. bought a new stake in Citius Pharmaceuticals in the 2nd quarter worth approximately $42,000. Finally, Heights Capital Management Inc. purchased a new stake in shares of Citius Pharmaceuticals during the 4th quarter worth approximately $622,000. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.